Search

Your search keyword '"Rayman, Nazik"' showing total 19 results
Start Over Author "Rayman, Nazik"
19 results on '"Rayman, Nazik"'

1. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A. M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert-Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J. W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W. C. J., van der Spek, Ellen, Leys, Rineke B. L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C. H. P., Sinnige, Harm A. M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark-David, and Zweegman, Sonja

Published
2021
Full Text
View/download PDF

2. Beyond static measurements: dynamic frailty improves survival prediction in multiple myeloma

Author

Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia A. M., van Kampen, Roel, van der Spek, Ellen, Bilgin, Yavuz M., Thielen, Noortje, Nijhof, Inger, Ludwig, Inge, de Waal, Esther G. M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert-Jan, Regelink, Josien C., Westerman, Matthijs, de Heer, Koen, Vekemans, Marie-Christiane, Durdu-Rayman, Nazik, de Graauw, Nicole C. H. P., Seefat, Maarten R., van de Donk, Niels W. C. J., Ypma, Paula F., Nasserinejad, Kazem, and Zweegman, Sonja

Published
2024
Full Text
View/download PDF

5. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study

Author

Stege, Claudia A. M., primary, Nasserinejad, Kazem, additional, van der Spek, Ellen, additional, Bilgin, Yavuz M., additional, Kentos, Alain, additional, Sohne, Maaike, additional, van Kampen, Roel J. W., additional, Ludwig, Inge, additional, Thielen, Noortje, additional, Durdu-Rayman, Nazik, additional, de Graauw, Nicole C. H. P., additional, van de Donk, Niels W. C. J., additional, de Waal, Esther G. M., additional, Vekemans, Marie-Christiane, additional, Timmers, Gert Jan, additional, van der Klift, Marjolein, additional, Soechit, Savita, additional, Geerts, Paul A. F., additional, Silbermann, Matthijs H., additional, Oosterveld, Margriet, additional, Nijhof, Inger S., additional, Sonneveld, Pieter, additional, Klein, Saskia K., additional, Levin, Mark-David, additional, and Zweegman, Sonja, additional

Published
2021
Full Text
View/download PDF

6. Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

Author

Smits, Febe, Groen, Kaz, Levin, Mark-David, Stege, Claudia, Van Kampen, Roel JW, Van Der Spek, Ellen, Bilgin, Yavuz M, Thielen, Noortje, Nijhof, Inger S., Ludwig, Inge, De Waal, Esther G.M., Sandberg, Yorick, Kentos, Alain, Timmers, Gert Jan, Regelink, Josien C, Westerman, Matthijs, de Heer, Koen, Vekemans, Marie Christiane, Durdu-Rayman, Nazik, Graauw, Nicole de, Seefat, Maarten R., van de Donk, Niels WCJ, Ypma, Paula F, Nasserinejad, Kazem, and Zweegman, Sonja

Published
2023
Full Text
View/download PDF

7. Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study.

Author

UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, Zweegman, Sonja, UCL - (SLuc) Centre du cancer, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, Stege, Claudia A M, Nasserinejad, Kazem, van der Spek, Ellen, Bilgin, Yavuz M, Kentos, Alain, Sohne, Maaike, van Kampen, Roel J W, Ludwig, Inge, Thielen, Noortje, Durdu-Rayman, Nazik, de Graauw, Nicole C H P, van de Donk, Niels W C J, de Waal, Esther G M, Vekemans, Marie-Christiane, Timmers, Gert Jan, van der Klift, Marjolein, Soechit, Savita, Geerts, Paul A F, Silbermann, Matthijs H, Oosterveld, Margriet, Nijhof, Inger S, Sonneveld, Pieter, Klein, Saskia K, Levin, Mark-David, and Zweegman, Sonja

Abstract

Frail patients with newly diagnosed multiple myeloma have an inferior outcome, mainly because of a high discontinuation rate due to toxicity. We designed a phase II trial specifically for frail patients, evaluating the efficacy and tolerability of ixazomib-daratumumab-low-dose-dexamethasone (Ixa-Dara-dex). Sixty-five patients, who were frail according to the International Myeloma Working Group frailty index, were treated with nine induction cycles Ixa-Dara-dex followed by maintenance with Ixa-Dara for a maximum of 2 years. The overall response rate on induction therapy was 78%. After a median follow-up of 22.9 months, median progression-free survival (PFS) was 13.8 months and 12-month overall survival (OS) was 78%. Median PFS and 12-month OS were 21.6 months and 92% in patients who were frail based on age > 80 years alone, versus 13.8 months and 78%, and 10.1 months and 70% in patients who were frail based on additional frailty parameters either ≤ 80 or > 80 years of age, respectively. In 51% of patients, induction therapy had to be discontinued prematurely, of which 6% because of noncompliance to study treatment, 9% because of toxicity, and 9% because of death (8% within 2 months, of which 80% because of toxicity). Quality of life improved during induction treatment, being clinically meaningful already after three induction cycles. Ixa-Dara-dex lead to a high response rate and improved quality of life. However, treatment discontinuation because of toxicity and early mortality, negatively influencing PFS and OS, remains a concern in frail patients. The outcome was heterogeneous across frail subpopulations. This should be taken into account in the design and interpretation of future studies in frail patients, to pave the way for more precise treatment guidance.

Published
2021

8. Improving the identification of frail elderly newly diagnosed multiple myeloma patients

Author

Stege, Claudia A.M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J.W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W.C.J., van der Spek, Ellen, Leys, Rineke B.L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C.H.P., Sinnige, Harm A.M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark David, Zweegman, Sonja, Stege, Claudia A.M., Nasserinejad, Kazem, Klein, Saskia K., Timmers, Gert Jan, Hoogendoorn, Mels, Ypma, Paula F., Nijhof, Inger S., Velders, Gerjo A., Strobbe, Leonie, Durdu-Rayman, Nazik, Westerman, Matthijs, Davidis-van Schoonhoven, Marjan A., van Kampen, Roel J.W., Beeker, Aart, Koster, Ad, Dijk, Amanda C., van de Donk, Niels W.C.J., van der Spek, Ellen, Leys, Rineke B.L., Silbermann, Matthijs H., Groen, Kaz, van der Burg-de Graauw, Nicole C.H.P., Sinnige, Harm A.M., van der Hem, Klaas G., Levenga, Henriette, Bilgin, Yavuz M., Sonneveld, Pieter, Levin, Mark David, and Zweegman, Sonja

Published
2021

11. Gelatinous bone marrow transformation due to extensive weight loss in median arcuate ligament syndrome.

Author

Matute, Lorena Miguelañez, Noord, Desiree van, Rayman, Nazik, and Guillen, Samara S

Abstract

A 34-year- old man was referred to the outpatient clinic because of progressive abdominal pain, weight loss and pancytopenia. His body mass index (BMI) had fallen to 14.2 kg/m2. A CT angiography (CTA) showed narrowing of the truncus coeliacus with poststenotic dilation, and duodenal biopsy revealed ischaemia establishing a rare diagnosis: median arcuate ligament syndrome (MALS). This explained the postprandial pain and minimal intake. Further pancytopenia workup was performed. The bone marrow displayed gelatinous marrow transformation (GMT), a rare disorder of unknown pathogenesis, which has been associated with severe malnutrition. The final diagnosis was pancytopenia secondary to GMT due to severe malnutrition caused by MALS. The abnormalities in the bone marrow may be reversible by restoring nutritional status. This case emphasises the awareness of GMT in patients with weight loss, malnutrition and cytopenias. To our knowledge, this is the first report demonstrating an association between pancytopenia and MALS. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

13. Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Author

Stege, Claudia A.M., primary, Nasserinejad, Kazem, primary, van der Spek, Ellen, primary, Van Kampen, Roel J.W., primary, Sohne, Maaike, primary, Thielen, Noortje, primary, Bilgin, Yavuz, primary, De Waal, Esther G.M., primary, Ludwig, Inge, primary, Leijs, Maria B.L., primary, Kentos, Alain, primary, Timmers, Gert Jan, primary, de Heer, Koen, primary, Westerman, Matthijs, primary, Vekemans, Marie Christiane, primary, Durdu-Rayman, Nazik, primary, van der Burg-de Graauw, Nicole C.H.P., primary, Van De Donk, Niels W. C. J., primary, Sonneveld, Pieter, primary, Klein, Saskia K., primary, Levin, Mark-David, primary, and Zweegman, Sonja, primary

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results